SSY GROUP Granted Pharmaceutical Production Registration Certificate for Diltiazem Hydrochloride Injection

Stock News04-27 12:08

SSY GROUP (02005) has announced that the group has obtained a pharmaceutical production registration certificate from China's National Medical Products Administration for Diltiazem Hydrochloride for Injection (10mg). The product is classified as a chemical drug category 4 and is considered to have passed the consistency evaluation. Diltiazem Hydrochloride for Injection is primarily used for treating supraventricular tachycardia, emergency management of abnormal hypertension during surgery, hypertensive emergencies, and unstable angina.

The board of directors is also pleased to announce that the group has received approval from the National Medical Products Administration for Propranolol Hydrochloride Injection (5ml: 5mg and 2ml: 2mg). This product falls under chemical drug category 3 and is likewise considered to have passed the consistency evaluation. Propranolol Hydrochloride Injection is mainly indicated for controlling supraventricular tachyarrhythmia and ventricular arrhythmia, effort angina, and pheochromocytoma (used in combination with alpha-blockers to manage tachycardia).

The group's Propranolol Hydrochloride active pharmaceutical ingredient has also been approved by the National Medical Products Administration for registration as an API used in marketed formulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1190248585?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 12:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190248585","market":"hk","top_or_hot":-1,"title":"SSY GROUP Granted Pharmaceutical Production Registration Certificate for Diltiazem Hydrochloride Injection","media":"Stock News","content":"<p>SSY GROUP (02005) has announced that the group has obtained a pharmaceutical production registration certificate from China's National Medical Products Administration for Diltiazem Hydrochloride for Injection (10mg). The product is classified as a chemical drug category 4 and is considered to have passed the consistency evaluation. Diltiazem Hydrochloride for Injection is primarily used for treating supraventricular tachycardia, emergency management of abnormal hypertension during surgery, hypertensive emergencies, and unstable angina.</p>\n<p>The board of directors is also pleased to announce that the group has received approval from the National Medical Products Administration for Propranolol Hydrochloride Injection (5ml: 5mg and 2ml: 2mg). This product falls under chemical drug category 3 and is likewise considered to have passed the consistency evaluation. Propranolol Hydrochloride Injection is mainly indicated for controlling supraventricular tachyarrhythmia and ventricular arrhythmia, effort angina, and pheochromocytoma (used in combination with alpha-blockers to manage tachycardia).</p>\n<p>The group's Propranolol Hydrochloride active pharmaceutical ingredient has also been approved by the National Medical Products Administration for registration as an API used in marketed formulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY GROUP Granted Pharmaceutical Production Registration Certificate for Diltiazem Hydrochloride Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY GROUP Granted Pharmaceutical Production Registration Certificate for Diltiazem Hydrochloride Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-27 12:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SSY GROUP (02005) has announced that the group has obtained a pharmaceutical production registration certificate from China's National Medical Products Administration for Diltiazem Hydrochloride for Injection (10mg). The product is classified as a chemical drug category 4 and is considered to have passed the consistency evaluation. Diltiazem Hydrochloride for Injection is primarily used for treating supraventricular tachycardia, emergency management of abnormal hypertension during surgery, hypertensive emergencies, and unstable angina.</p>\n<p>The board of directors is also pleased to announce that the group has received approval from the National Medical Products Administration for Propranolol Hydrochloride Injection (5ml: 5mg and 2ml: 2mg). This product falls under chemical drug category 3 and is likewise considered to have passed the consistency evaluation. Propranolol Hydrochloride Injection is mainly indicated for controlling supraventricular tachyarrhythmia and ventricular arrhythmia, effort angina, and pheochromocytoma (used in combination with alpha-blockers to manage tachycardia).</p>\n<p>The group's Propranolol Hydrochloride active pharmaceutical ingredient has also been approved by the National Medical Products Administration for registration as an API used in marketed formulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1190248585","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190248585","pubTimestamp":1777262901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SSY GROUP (02005) has announced that the group has obtained a pharmaceutical production registration certificate from China's National Medical Products Administration for Diltiazem Hydrochloride for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","02005":"石四药集团"},"translate_title":"SSY集团获得盐酸地尔硫卓注射液药品生产注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"SSY GROUP (02005) has announced that the group has obtained a pharmaceutical production registration certificate from China's National Medical Products Administration for Diltiazem Hydrochloride for Injection (10mg). The product is classified as a chemical drug category 4 and is considered to have passed the consistency evaluation. Diltiazem Hydrochloride for Injection is primarily used for treating supraventricular tachycardia, emergency management of abnormal hypertension during surgery, hypertensive emergencies, and unstable angina.\nThe board of directors is also pleased to announce that the group has received approval from the National Medical Products Administration for Propranolol Hydrochloride Injection (5ml: 5mg and 2ml: 2mg). This product falls under chemical drug category 3 and is likewise considered to have passed the consistency evaluation. Propranolol Hydrochloride Injection is mainly indicated for controlling supraventricular tachyarrhythmia and ventricular arrhythmia, effort angina, and pheochromocytoma (used in combination with alpha-blockers to manage tachycardia).\nThe group's Propranolol Hydrochloride active pharmaceutical ingredient has also been approved by the National Medical Products Administration for registration as an API used in marketed formulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190248585","isCrawlerRequest":true}